Investigational drug · Phase 2
MAS825
Also called: Arumakimig
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
9
Any phase or sponsor naming "MAS825"
First trial start
2019
Feb 27, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MAS825", any sponsor or status.
Conditions studied
As listed on its trial records.
- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
- Still´s Disease
- VEXAS Syndrome
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "MAS825" as an intervention, largest first.
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03827798 · 248 participants · Start Feb 27, 2019 · Primary completion Dec 4, 2024
Drug: CFZ533; Placebo to CFZ533 and 9 more · For: Hidradenitis Suppurativa
Sites: Clearwater, Florida; Orange Park, Florida; Tampa, Florida · 36 sites in all
- Study of Efficacy and Safety of MAS825 in Patients With COVID-19Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04382651 · 140 participants · Start Jun 11, 2020 · Primary completion Jan 6, 2021
Drug: MAS825; Standard of Care (SoC) · For: COVID-19 Pneumonia, Impaired Respiratory Function
Sites: Chula Vista, California; Glendale, California; Irvine, California · 21 sites in all
- A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) PeriodPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07748624 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 26, 2028
Drug: Arumakimig; Placebo and 1 more · For: VEXAS Syndrome
Sites: Yokohama, Japan; Suita, Japan; Hachiōji, Japan · 6 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04665154 · 80 participants · Start Jun 7, 2019 · Primary completion Aug 3, 2022
Drug: MAS825; Placebo · For: Healthy Volunteers
Sites: Tempe, Arizona; Overland Park, Kansas; Mere Way, United Kingdom
Novartis PharmaceuticalsNovartis (NVS)
NCT06097663 · 31 participants · Start Feb 15, 2024 · Primary completion Oct 27, 2024
Drug: MAS825; MAS825 Placebo and 2 more · For: Coronary Heart Disease; Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Sites: St Louis, Missouri; Nashville, Tennessee; Montreal, Canada · 6 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07203001 · 30 participants (planned) · Start Nov 3, 2025 · Primary completion Apr 22, 2027
Drug: MAS825 · For: Still´s Disease
Sites: Cincinnati, Ohio; Portland, Oregon; Salt Lake City, Utah · 24 sites in all
- Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04641442 · 17 participants · Start Dec 18, 2020 · Primary completion Oct 14, 2025
Drug: MAS825; Placebo · For: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Sites: Cincinnati, Ohio; Philadelphia, Pennsylvania; Houston, Texas · 12 sites in all
- A Single-patient Clinical Trial of MAS825 in a Patient With XIAP DeficiencyPivotal-lookingCompleted
The Hospital for Sick ChildrenAcademic, hospital or other
NCT06309823 · 1 participants · Start Feb 8, 2023 · Primary completion Jan 17, 2024
Drug: MAS825 · For: X-linked Lymphoproliferative Syndrome Type 2 (XLP-2)
Sites: Toronto, Canada
- Managed Access Programs for MAS825, ArumakimigTemporarily not available
Novartis PharmaceuticalsNovartis (NVS)
NCT07889310
Drug: Arumakimig · For: Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications
Newest research
PubMed records naming it or its code names, newest first.
- Immunomodulation in paediatric inflammatory interstitial lung diseases: towards mechanism-based targeted therapies, a focus on the anti-cytokines.
Gonsard A, Fremond ML, Hadchouel A · Paediatr Respir Rev 2026
- Sustained remission after bispecific antibody anti-IL-1β/anti-IL-18 therapy in a severe childhood Still's disease with recurrent macrophage activation syndrome.
Cognard J, Sormani J, Freppel M, et al. · Joint Bone Spine 2025
- Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome.
Caorsi R, Bertoni A, Matucci-Cerinic C, et al. · Rheumatology (Oxford) 2025
- Experience of anti-IL-1β and anti-IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome.
Çağlayan Ş, Ulu K, Sözeri B · Rheumatology (Oxford) 2024
- Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function.
Hakim AD, Awili M, O'Neal HR, et al. · Clin Exp Immunol 2023
- Improvement of Refractory Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18.
Rood JE, Rezk A, Pogoriler J, et al. · J Clin Immunol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.